Oruka Therapeutics, Inc. (ORKA) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $68.47: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality.
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing extended half-life monoclonal antibodies for psoriasis and other inflammatory conditions. Lead programs ORKA-001 (IL-23p19, Phase 2) and ORKA-002 (IL-17A/F, Phase 2) are licensed from Paragon... Read more
Sell if holding. Engine safety override at $68.47: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Score 5.3/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 60d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — Oruka Therapeutics, Inc.
Latest news
- NEWS Oruka Therapeutics Expands ORKA-001 License To All Indications, Adding Future IBD Rights Under Paragon Amendment — benzinga Jun 1, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price Target — benzinga May 18, 2026 positive
- NEWS BTIG Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target — benzinga May 14, 2026 neutral
- NEWS Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate — benzinga May 13, 2026 positive
- NEWS Oruka Therapeutics Files Prospectus For Offering 9.66M Common Shares — benzinga Apr 29, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineORKA-001 and ORKA-00210-K Item 1A: 'We are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002'
- HIGHSupplierParagon Therapeutics10-K Item 1: 'We have entered into license agreements with Paragon pursuant to which Paragon granted us a royalty-bearing, world-wide, exclusive license'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $68.47: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 16%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Prior stop was $63.68. Score 5.3/10, moderate confidence.
Take-profit target: $123.69 (+80.6% upside). Prior stop was $63.68. Stop-loss: $63.68.
Concentration risk — Pipeline: ORKA-001 and ORKA-002; Concentration risk — Supplier: Paragon Therapeutics; Quality below floor (1.5 < 4.0).
Oruka Therapeutics, Inc. trades at a P/E of N/A (forward -26.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover ORKA with a consensus score of 4.4/5. Average price target: $142.
What does Oruka Therapeutics, Inc. do?Oruka Therapeutics is a clinical-stage biopharmaceutical company developing extended half-life monoclonal antibodies...
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing extended half-life monoclonal antibodies for psoriasis and other inflammatory conditions. Lead programs ORKA-001 (IL-23p19, Phase 2) and ORKA-002 (IL-17A/F, Phase 2) are licensed from Paragon Therapeutics; the company has no approved products and generates no product revenue.